New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›CSOP›03174

03174

CSOP Hang Seng Biotech ETF

Passive ETF Equity

Not rated

The 03174 Exchange Traded Fund (ETF) is provided by CSOP. It is built to track an index: Hang Seng Biotech Index. The 03174 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

HK$3.53

N/A

Data as of 11/04/26

1D price range

N/A

52W price range

N/A

YTD Perf.

+3.51%

YTD Flows

Annualized volatility

Fund AuM

€103M

Share class AuM

€103M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

HK0000756202

TER

0.99%

Inception date

7/20/2021

Issuer

CSOP

Benchmark

Hang Seng Biotech Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
83069 ChinaAMC Hang Seng Biotech ETF	+3.06%
KURE KraneShares MSCI All China Health Care Index ETF	-0.46%
371470 Mirae Asset TIGER Biotech Solactive ETF	-0.62%
09820 Global X China Biotech ETF	-

API

PerformanceDec 31, 2025 - Nov 4, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

97.04%

Consumer Non-Cyclicals

2.61%

Unavailable

0.35%

Latest 03174 news

No content available for this fund

FAQ about 03174

03174 is a passively managed ETF that invests in the APAC Blended Cap segment.

03174 tracks the Hang Seng Biotech Index - HKD, through a optimized sampling replication method.

03174 carries a total expense ratio (TER) of 0.99%.

03174 was introduced to the market on July 20, 2021.

CSOP Hang Seng Biotech ETF, 03174, is provided by CSOP. Learn more about CSOP here.

03174 oversees €103M in assets as of November 4, 2026.

03174 follows a distributing dividend policy, meaning it pays out income to investors.

As of September 30, 2026, 03174 has significant geographic allocations in China, Hong Kong and Switzerland.

As of September 30, 2026, 03174 focuses largely on Healthcare and Consumer Non-Cyclicals.

As of September 30, 2026, 03174 holds 30 positions in its portfolio, with 85.66% of assets concentrated in its top 15 holdings.

As of September 30, 2026, 03174 top three holdings include WuXi Biologics (Cayman), Inc., BeOne Medicines Ltd. and Innovent Biologics, Inc..

The base currency of 03174 is HKD.

Top 10 holdings

Data as of 09/30/26

WuXi Biologics (Cayman), Inc.

10.73%

BeOne Medicines Ltd.

10.00%

Innovent Biologics, Inc.

9.24%

WuXi AppTec Co., Ltd.

8.93%

CSPC Pharmaceutical Group Ltd.

7.23%

Akeso, Inc.

7.13%

Genscript Biotech Corp.

5.68%

Sino Biopharmaceutical Ltd.

5.23%

Hansoh Pharmaceutical Group Co., Ltd.

4.76%

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

3.33%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

CSOP Hang Seng Biotech ETF

FAQ about 03174

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US